SCHEMBL3554330

SCHEMBL3554330

COC(=O)[C@H]1C[C@H](F)CN1C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PEPD P12955 1/20 0.48
XPNPEP1 Q9NQW7 1/20 0.48
PTPN1 P18031 1/20 0.43
MMP2 P08253 2/20 0.42
ANPEP P15144 2/20 0.42
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 1/20 0.41
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
DPP4 P27487 6/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HSD11B1 P28845 1/20 0.36
P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476146 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL91557 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL4250662 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL3643891 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL3552873 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL2995724 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL18591298 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL19219868 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL29827776 0.91 NR1H2 (0.39) PEPDXPNPEP1PTPN1NR1H2NR1H3
SCHEMBL29947782 0.91 NR1H2 (0.39) PEPDXPNPEP1PTPN1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630539-B2 Amide compound, pharmaceutical composition and use thereof ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) 2026-05-19 US disclosed
EP-4714446-A2 PHARMACEUTICAL COMPOUNDS Nxera Pharma UK Limited (GB) 2026-03-25 EP disclosed
EP-4253375-B1 AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF ARTIVILA SHENZHEN INNOVATION CENTER LTD (CN) 2026-01-07 EP disclosed
CN-115867282-B 5-Amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer use 奈克斯拉制药英国有限公司 2025-05-27 CN disclosed
WO-2025002302-A1 PYRIMIDO-PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 广东东阳光药业股份有限公司 2025-01-02 WO disclosed
CN-119219668-A Pyrimidopyridine compounds, pharmaceutical compositions thereof and uses thereof 广东东阳光药业股份有限公司 2024-12-31 CN disclosed
CN-118930520-A Novel histone acetyl transferase p300 bromodomain inhibitor and pharmaceutical composition and application thereof 复旦大学 2024-11-12 CN disclosed
US-12139497-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2024-11-12 US disclosed
CN-118791506-A KRAS inhibitor compounds, pharmaceutical compositions thereof and uses thereof 广东东阳光药业股份有限公司 2024-10-18 CN disclosed
WO-2024213122-A1 KRAS INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 广东东阳光药业股份有限公司 2024-10-17 WO disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 US disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 EP disclosed
US-20100174096-A1 Methods for Production of Optically Active Fluoropyrrolidine Derivatives IM&T RESEARCH, INC. (US) 2010-07-08 US disclosed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-7585885-B2 Pyrrolidine derivatives useful as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-09-08 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630539-B2 Amide compound, pharmaceutical composition and use thereof JAK2, JAK1, JAK3 PEPD 3146/4885XPNPEP1 3105/4885PTPN1 62/4885
US-20100174096-A1 Methods for Production of Optically Active Fluoropyrrolidine Derivatives QDPR, FDPS, DPYD PEPD 190/4885XPNPEP1 1225/4885PTPN1 4849/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 PEPD 77/4885XPNPEP1 222/4885PTPN1 4552/4885
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF TRPV1, FGFR3, GPR17 PEPD 1687/4885XPNPEP1 3517/4885PTPN1 47/4885
US-12139497-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders CFD, F12, F3 PEPD 80/4885XPNPEP1 345/4885PTPN1 3140/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PEPD 203/4885XPNPEP1 428/4885PTPN1 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.